We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Gilead Sciences Inc | NASDAQ:GILD | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.805 | -1.22% | 65.135 | 65.13 | 65.14 | 65.60 | 64.89 | 65.62 | 3,384,304 | 20:12:03 |
From Oct 2023 to Apr 2024
Gilead agreed in 2020 to buy Trodelvy-maker Immunomedics for $21 billion. "Gilead Says Trodelvy Lung Cancer Trial Didn't Meet Primary Endpoint" at 8:47 a.m. ET incorrectly said Gilead agreed in 2022 to buy Immunomedics.
(END) Dow Jones Newswires
January 22, 2024 09:17 ET (14:17 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
1 Year Gilead Sciences Chart |
1 Month Gilead Sciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
